ArticleOtology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology2025
Mastoid Obliteration Using S53P4 Bioactive Glass Versus Mastoidectomy Alone for Refractory Chronic Suppurative Otitis Media.
Article in Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomaterials and Tissue Engineering Strategies for Mastoid Obliteration: A Systematic Review of the Clinical and Preclinical Evidence.Journal of clinical medicine · 2026Review
- Effect of adding biologic agents to disease-modifying anti-rheumatic drugs for refractory chronic suppurative otitis media: comparative outcomes and cytokine-driven mechanisms.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo present the outcomes of mastoid obliteration using S53P4 bioactive glass (BAG) for refractory chronic suppurative otitis media (CSOM) and compare these to mastoidectomy alone. STUDY
designRetrospective comparative cohort study.
settingSingle-center study. PATIENTS: All cases that underwent a canal wall up (CWU) mastoidectomy between 2010 and 2022 for refractory CSOM. Inclusion criteria were refractory purulent otorrhea preoperatively as indicated by Merchant grade 2 or 3 despite conservative treatment for at least 6 months, at least 1 year of follow-up and mastoid involvement as indicated by subtotal or total opacification on the preoperative imaging. Patients with cholesteatoma were excluded.
interventionsMastoid obliteration using S53P4 BAG. MAIN OUTCOME MEASURESS: Merchant grade 1-year postoperatively, incidence of revision surgery during follow-up, frequency of tympanic membrane perforations, ventilation tube need, and audiological outcomes.
resultsIn total, 124 obliteration cases and 84 non-obliteration cases were included. At 1-year postoperatively, the dry ear rate was 116 of 124 (94%) in the obliteration cohort and 71 of 84 (85%) in the non-obliteration cohort (p = 0.02). Continuous discharge (merchant grade 3) was only observed in one non-obliteration case. During follow-up, revision surgery due to refractory otorrhea was necessary in none of the obliteration cases and 10 non-obliteration cases (p < 0.001). The frequency of tympanic membrane perforations, ventilation tube need, and audiological results were comparable between the two groups.
conclusionsOur study indicates that for refractory cases of CSOM, mastoid obliteration using BAG results in superior outcomes compared to mastoidectomy alone. It results in significantly less postoperative otorrhea and revision operations and should therefore be considered. LEVEL OF EVIDENCE: 3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.